OS Therapies reports Q2 results

* OS Therapies press release [https://seekingalpha.com/pr/20204527-os-therapies-reports-second-quarter-2025-financial-results-and-provides-business-update] (NYSE:OSTX [https://seekingalpha.com/symbol/OSTX]): Q2  Reported final EFS data (35% vs. 20%, p = 0.0197) showing a statistically significant benefit from the Company's 40 patient Phase 2b clinical trial for OST-HER2-treated patients in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma when compared with historical control at MIB Factor
* $4.2 million capital raise, closed July 11, 2025 via warrant exercise inducement and exchange offering, extends cash runway into mid-2026

MORE ON OS THERAPIES

* Seeking Alpha’s Quant Rating on OS Therapies [https://seekingalpha.com/symbol/OSTX/ratings/quant-ratings]
* Historical earnings data for OS Therapies [https://seekingalpha.com/symbol/OSTX/earnings]
* Financial information for OS Therapies [https://seekingalpha.com/symbol/OSTX/income-statement]